- Home
- SCNI
as of 08-27-2026 12:08pm EST
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 1.4M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 512.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | 50.00 |
| 52 Week Low/High: | $0.21 - $3.58 | Next Earning Date: | 05-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -956.67 | Index: | N/A |
| Free Cash Flow: | -8101000.0 | FCF Growth: | N/A |
Compare SCNI vs Leading Stocks
See how SCNI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SCNI Scinai Immunotherapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.